KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing oral therapies for hereditary angioedema (HAE). Its lead product, EKTERLY (sebetralstat), received FDA approval in July 2025 and the company has begun U.S. commercial operations while also pursuing ex-U.S. partnering opportunities.

−374,1 %

−366,9 %

5.35

5.28

— KalVista Pharmaceuticals, Inc.
%
Commercial product sales85% Sales of EKTERLY in the U.S. following FDA approval.
License and collaboration revenue15% Upfront, milestone, and royalty income from regional licensing deals.
Clinical development programs0% Research and development work on sebetralstat and other pipeline candidates.

The core customer base is allergists and immunologists, who account for most HAE prescribing and claims in the U.S...

  • U.S. HAE prescribersprimary

    Allergists and immunologists who prescribe EKTERLY for acute HAE attacks and drive adoption.

  • Commercially insured HAE patientsprimary

    Patients who receive EKTERLY through specialty pharmacy channels and benefit programs.

  • Payers and pharmacy benefit managersprimary

    Organizations that determine formulary access, reimbursement, and patient out-of-pocket costs.

  • Specialty pharmaciessecondary

    Channel partners that dispense product, manage inventory, and support distribution.

  • International license partnerssecondary

    Companies such as Kaken and Pendopharm that commercialize or seek approval in local markets.

KalVista’s commercial focus is currently the United States, where EKTERLY launched after FDA approval in July 2025...

  • •United States is the first commercial market for EKTERLY
  • •Japan is licensed to Kaken for local commercialization
  • •Canada is licensed to Pendopharm for regulatory and commercial rights
  • •Company retains supply and regulatory responsibilities for Japan
  • •International expansion is expected to be partner-led rather than direct

KalVista’s strategy is to convert EKTERLY from a development asset into a commercial product in the U.S...

01
U.S. commercialization of EKTERLYshort-term

Near-term value creation depends on converting FDA approval into prescriptions and payer coverage.

02
International partneringmedium-term

Licensing reduces the cost of global expansion while preserving upside through milestones and royalties.

03
Supply and regulatory executionshort-term

Commercial success depends on reliable manufacturing, regulatory maintenance, and product availability.

KalVista is still highly dependent on EKTERLY, so commercial uptake, payer access, and physician adoption will largely...

high

Dependence on EKTERLY commercialization

The company’s value and revenue base are concentrated in a single approved product.

Scope
U.S. launch and future ex-U.S. royalties
Materiality
high
high

Insufficient market acceptance

Prescriber adoption and payer coverage determine whether the launch converts into durable sales.

Scope
Allergists, immunologists, specialty pharmacy channel
Materiality
high
high

Funding and dilution risk

The company has a history of losses and may need more capital to support commercialization and R&D.

Scope
Operating cash needs and launch investment
Materiality
high
medium

Manufacturing and supply risk

Product availability depends on third-party manufacturing and distribution execution.

Scope
EKTERLY supply chain
Materiality
medium
medium

Competitive pressure in HAE

Other pharmaceutical companies market or develop therapies for the same indication.

Scope
HAE acute treatment market
Materiality
medium
Revenue deductions and reserves
Can materially change reported EKTERLY revenue in early launch periods
Milestone and royalty accounting
Affects collaboration revenue and deferred revenue balances
Clinical and commercial accruals
Can cause quarter-to-quarter expense volatility
Lease accounting
Creates right-of-use assets and lease liabilities

BIOCRYST PHARMACEUTICALS INC

BCRX · Biological Products, (No Diagnostic Substances)

Milestone Pharmaceuticals Inc.

MIST · Pharmaceutical Preparations

KALA BIO, Inc.

KALA · Pharmaceutical Preparations

Karyopharm Therapeutics Inc.

KPTI · Pharmaceutical Preparations

PALVELLA THERAPEUTICS, INC.

PVLA · Pharmaceutical Preparations

Akebia Therapeutics, Inc.

AKBA · Pharmaceutical Preparations

: 28/04/2026